Nyob rau hauv lub teb ntawm lub plab zom mov (GI) kev kho mob cancer, kev tshawb nrhiav phiaj xwm tseem ceeb rau kev tawg los ntawm kev ua tau zoo ntawm kev ua tau zoo ntawm bottenmenecks. CDH17 tau tawm los ua "Lub Hnub Qub Rising" hauv cov tshuaj ntsuab R & D vim tias muaj kev kho mob qog nqaij hlav gi cov qog nqaij hlav thiab mob plab.
01 ib qho tsis sib haum "cov qog -} Tsom rau biomarker"
Cov kev muaj txuj ci biological ntawm CDH17 (Cadherin-17) ib txwm ua rau nws lub hom phiaj zoo tshaj plaws ntawm kev ua "zais hauv cov ntaub so ntswg zoo tab sis nthuav tawm hauv cov nqaij qog nqaij tawv."
Hauv cov tib neeg noj qab nyob zoo, CDH17 yog ib qho tseem ceeb rau cov ncej puab ntawm cov hnyuv epithelial hlwb thiab zais hauv kev sib tshuam. Qhov no "zais" faib tawm tiv thaiv kev nkag tau los ntawm antibody {} Raws cov tshuaj, zam kev puas tsuaj rau cov ntaub so ntswg ib ce thiab tswj kev kho mob ib txwm muaj thiab tswj kev kho mob ib txwm muaj thiab txhim kho kev nyab xeeb. Nyob rau hauv Gi cancer, txawm li cas los xij, CDH17 hais tawm txoj kev hloov pauv txawv: Nws cov theem nce ntxiv, nrog lub plab zom zaws 50-90% ntawm lub plab zom mov, xim huv si gi cancer. Ntxiv mus, nws rov qab los ntawm daim nyias nyias rau saum npoo ntawm cov kabmob kheesxaws, ua kom raug rau cov tshuaj.
Qhov kev sib txawv ntawm ib txwm muaj thiab cov nqaij qog nqaij yog CDH17 tus yuam sij sib tw kom zoo dua. Nws ua rau cov tshuaj kom zoo li "tus cuaj luaj uas xaiv tau thiab khi rau cov kabmob qog nqaij hlav, muaj txiaj ntsig zoo kawg nkaus, tsis muaj txiaj ntsig" ntawm kev kho mob ntawm lub hom phiaj kho.
02 Tus neeg tsav tsheb tseem ceeb ntawm GI
CDH17 tsis yog ib leeg biomarker; Nws tseem ua haujlwm ua tus tsav "ua haujlwm" hauv kev pib, kev nce qib, thiab cov tshuaj tiv thaiv ntawm GI cancer, txuas ntxiv ntawm qhov chaw kuaj mob ntawm kev sib tw nws.
Hauv cov qog ua si thiab kev txeeb chaw, CDH17 cuam tshuam cov ntaub so ntswg kom ruaj khov los ntawm kev cuam tshuam nrog intercellular junctions. Nquag, CDH17 pab tswj kev mob plab hnyuv epithelial kev ncaj ncees ntawm kev khi rau cov hlwb uas nyob ib sab. Txawm li cas los xij rau cov qog nqaij hlav cancer, txawm li cas los xij, nws qhov kev tshaj tawm hauv lub cav los txhawm rau tshem tawm cov ncauj lus hauv lub nroog, txeeb chaw rau hauv ib puag ncig cov ntaub so ntswg, thiab metastasize.
Nyob rau hauv Angiogenesis, CDH17 tsis ncaj ncees tswj kev qhia tseeb kawg li kev loj hlob endothelial kev tshaj tawm (vegf) hais tawm. Los ntawm kev txhawb nqa vegf zais cia, nws nrawm qhov tsim ntawm cov qog ntshav, muab cov pa oxygen thiab cov as-ham los txhawb kev loj hlob sai sai.
Qhov tseem ceeb, CDH17 tau txuas rau kev kho kev tiv thaiv. Cov kev tshawb fawb soj ntsuam qhia tias CDH17 qhov kev qhia feem ntau tau raug kho hauv Gi cov kabmob tiv thaiv kev siv tshuaj Gi, li, Fluinum- raws tshuaj). Nws txo cov tshuaj rhiab los ntawm modulating cov kev ua yeeb yam lossis hom tshuaj hloov tshuaj transporter lossis {{}}} cov protein uas muaj feem xyuam, ua rau kev kho tsis ua haujlwm. Lub hom phiaj CDH17 yuav yog rov qab tiv thaiv, muab cov kev xaiv tshiab rau cov neeg mob refactory.
03 CDH17 Kev Txhim Kho Tshuaj: Kev vam khom kev vam meej
Nrog kev lees paub loj hlob ntawm CDH17 lub peev xwm, ntau lub tuam txhab tau muaj cov tshuaj uas muaj kev sib tw siab tshaj plaws ntawm kev txhim kho.
Ntshai Biotech: Lawv lil - 054 {{} Cormy CD3} {{{{{} reactivity nrog lwm Cadherins. Nws ua cov qog muaj zog muaj zog}}}}}}}} pah17-zoo hlwb, tsis muaj tshuaj lom rau cdh17-tsis zoo hlwb. Lub caij no, LBL-054-ADC, siv tus qauv sib txuas, ua kom pom kev zoo rau cov tshuaj tiv thaiv hluav taws xob, thiab ua kom zoo rau kev ua kom zoo dua qub (dar}), nrog cov qauv muaj zog hauv cov qauv ua ntej.
Huadong Tshuaj: HDM2017, ANC Lub Hom Phiaj CDH17 nrog rau sab todoisomerase i free} {2} {{2} rau theem kuv tau sim. Cov ntaub ntawv ua qauv qhia tau muaj txiaj ntsig zoo hauv Coliltalal, Pancreatic, thiab Gastric Cancer Qauv.
Yizheng biotech: YL217, CDH17-VIM ADC, tau nkag mus rau theem Kuv kev sim tshuaj, uas muaj peev xwm sim rau GI DYCERS vim yog CDH17 qhov muaj feem ntau hauv cov qog no.
Mabwell Biotech: 7MW4911, ANC siv site -} {{}} {ove} {ove} {Riveistant cov neeg, thiab yog tam sim no nyob rau hauv kev txhim kho zoo.
Simcere party: SCR - A008, A ANHIBIZED ant antisomomom thiab dab} CDH17} {4 4}}
Lanova Kev Kho Mob: Lm {{- 350, tsim nyob rau cov qog nqaij hlav ntxiv hauv xenogyRapy cancer, thiab muaj FDA Ind Cancer.
Vasabio: VBC108, Bispecific Art Hom Phiaj CDH17 thiab CLDN18.2, Kev Kheev Mus Dual {}} {} Cov Ntaub Ntawv Txhawb Nqa Hauv Gi cancer, txhawb nqa los ntawm cov ntaub ntawv muaj zog.
Bioray Biotech: Br116, A ADC nrog rau tib neeg cov tshuaj tiv thaiv kev tiv thaiv kuv cov kev nyab xeeb (dar =4=4 {1} =4
Bio - thera cov kev daws teeb meem: Bsi {{- 721, A ARC nrog cov tshuaj tiv thaiv qog thiab cov tshuaj tiv thaiv MMA, intege payload,
Sotio Biotech: SOT109, an ADC with a fully human CDH17 antibody and topoisomerase I inhibitor, is expected to submit an IND in Q2 2026, targeting the >90% ntawm GI cancer qhia CDH17.
04 Cov Sijhawm thiab Cov Nyuaj Siab
Txawm hais tias kev nce qib sai sai, soj ntsuam soj ntsuam ntawm CDH17-tsom cov kev kho mob ntsib tab sis kuj tuav cov sijhawm tseem ceeb.
Cov kev sib tw tseem ceeb xws liTumal heterogeneity(Sib txawv cdh17 hais tawm ntawm cov neeg mob) xav kom cov neeg kuaj xyuas khub, thiabTawm - phiaj hom phiaj toxicity tswjKom txo qis kev cuam tshuam rau cov ntaub so ntswg ib txwm.
Cov tsam thawj tshwm sim los ntawm lub siab tsis xav tau nyob rau hauv cov kabmob Gi siab, qhov twg cov kev kho tam sim no muaj kev muaj txoj sia nyob tsawg. Kev nce qib hauv ADC thiab Bispecious tshuaj tiv thaiv tshuab yuav txhim kho kev ua tau zoo-}}}}}}}}}} Cov tshuaj sharecific, thaum bispecific siv ntau lub hom phiaj.
Nrog kev tshawb xyuas cov kev kuaj mob thiab kev tshawb fawb tob, CDH17-hom phiaj kho kom dhau los ua qhov kev kho mob cancer, tshwj xeeb rau cov neeg ua haujlwm siab thiab resistant.
05 Xaus
Los ntawm kev tshawb fawb yooj yim rau kev tsim tshuaj yeeb, CDH17 tau tsim muaj cov raj xa hluav taws xob R & Dhuav, qhib tshiab txoj cai rau GI cancer kev kho. Thaum cov nyom xws li qog heterogeneity thiab cov tshuaj muaj tseeb nyob, kev nce qib tam sim no yog kev cog lus.
Raws li thev naus laus zis thiab kev tshawb fawb ua ntej, CDH17-kev cia siab rau kev ua kom muaj txoj sia ntev thiab qhov kawg ntawm kev kho mob ntawm sab hauv.
Tuaj txog::
1.Van der flier lg, clevers H.Fm cells, tus kheej {2} {{2} {{2 rov qab nyob rau hauv lub plab zom mov epithholog [j].
2.Li y, Zhang H, Wang J, et al.ce Ot Al.cy of pattin Cancery
3.Koj JS, Park Jy, Lee JH, et al.cdh17 raws li cov qog nqaij hlav: Koom haum cov qog nqaij hlav ntawm oncology, 2021,59 (2): 387-398.
4.Official tshaj tawm los ntawm cov tais Biotech, Huadong tshuaj, yizheng biotech, thiab lwm yam.
